Thirdline antiretroviral therapy including raltegravir RAL darunavir DRVr andor etravirine ETR is well tolerated and achieves durable virologic suppression over 144 weeks in resourcelimited settings ACTG A5288 strategy trial

Anchalee AvihingsanonMichael D. HughesRobert SalataCatherine GodfreySharlaa Badal-FaesenLerato MohapiE et al2023-10-172023-10-17SCOPUS17582652https://hdl.handle.net/10539/36761Thirdline antiretroviral therapy including raltegravir RAL darunavir DRVr andor etravirine ETR is well tolerated and achieves durable virologic suppression over 144 weeks in resourcelimited settings ACTG A5288 strategy trial